AstraZeneca & Emulate to bring advanced organ-on-chip tech in labs
Category: #health  By Saipriya Iyer  Date: 2018-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca & Emulate to bring advanced organ-on-chip tech in labs

AstraZeneca Plc, a biopharma firm headquartered in the UK, has entered into a collaboration with Emulate Inc. to include organ-on-a-chip technology into its R&D program. As per authentic sources, the strategic move is aimed toward marking an upsurge in the technological growth of the firm.

Reportedly, the terms and conditions of the deal state that Emulate’s researchers will be working in co-operation with AstraZeneca scientists at the latter’s IMED (Innovative Medicines & Early Development) labs. For the record, the two firms had begun to jointly work on the technology in 2013.

Lorna Ewart, the head of microphysiological systems at AstraZeneca, has stated that the pharma giant is looking forward to applying the new technology across various areas of treatment and studying the safety & efficiency of the novel medicine candidates. She has further claimed that AstraZeneca has become the first Pharma organization across the globe to set in organ-chips in its own labs.

Medical experts are of the view that the use of new technology by AstraZeneca in its labs will support its R&D decision making processes in the years to come. The technology is speculated to help the firm in accurately judging the adverse as well as non-adverse impact of the drug candidates and gain in-depth insights into the mechanisms of the disease with an objective to enhance the procedure of drug discovery.

Both Emulate Inc. and AstraZeneca are expected to make a combined effort to build the functionalities of three of Emulate’s organ chips that include Glomerulus Kidney-Chip, Lung Tumor-Chip, and Lung-Chip. Geraldine Hamilton, the CEO of Emulate Inc., has announced that the firm aims to promote the new technology and set it as a standard across the pharma sector. Reportedly, the preliminary stage of the deal is likely to utilize Emulate Inc.’s Liver-Chip for safety testing of drug candidates across AstraZeneca’s product pipeline.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...

Amazon unveils $2 billion climate fund to help decarbonize economies
Amazon unveils $2 billion climate fund to help decarbonize economies
By Saipriya Iyer

Amazon, the renowned technology and online retail giant, has reportedly announced a new initiative that would help efforts to develop sustainable technologies, products, and services that would allow Amazon and several...